Research
Hormonal
Rare deleterious variants in the gene CORO1A are significantly associated with changes in BMI at the population level, identifying it as a novel genetic factor in obesity risk.
Genetic testing may reveal variants in the CORO1A gene that predispose individuals to higher BMI. This is a newly identified genetic risk factor.
GoodSupportsHIGH confidence
our analysis also highlighted... CORO1A... which encodes a WD repeat protein... a gene previously unlinked with obesity.
Why this rating
Large sample size (UK Biobank n=419,692) and significant p-value (P=5.6x10^-6).
Source
Human HYPOMAP: A comprehensive spatio-cellular map of the human hypothalamus
John A. Tadross et al. · bioRxiv (Cold Spring Harbor Laboratory) · 2023
DOI 10.1101/2023.09.15.557967
preprint · n=433369Cited 8×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP1R-expressing neurons in the human hypothalamus, specifically those co-expressing POMC in the arcuate nucleus and AVP in the paraventricular/supraoptic nuclei, are the primary neural targets mediating the appetite-suppressing effects of GLP-1 receptor agonists like semaglutide.Good
- GIPR (Gastric Inhibitory Polypeptide Receptor) is expressed in human hypothalamic ependymal cells surrounding the third ventricle, suggesting a potential mechanism for how GIPR-targeting drugs like tirzepatide access the brain.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →